Ignite Creation Date:
2025-12-24 @ 9:34 PM
Ignite Modification Date:
2026-03-06 @ 10:47 AM
Study NCT ID:
NCT02478632
Status:
COMPLETED
Last Update Posted:
2020-10-19
First Post:
2015-05-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen
Sponsor:
ViiV Healthcare
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | HIV Infections | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | tenofovir disoproxil fumarate | View |
| None | dolutegravir plus rilpivirine | View |
| None | two-drug regimen | View |
| None | bone mineral density | View |
| None | dual energy X-ray absorptiometry (DEXA) | View |
| None | Human Immunodeficiency Virus-1 | View |
| None | nucleoside reverse transcriptase inhibitor -sparing regimen | View |
| None | integrase inhibitor | View |